Biological disease-modifying agents are transforming the treatment of autoimmune rheumatic diseases
Over the past decade, the advent of biological disease-modifying agents has led to transformational changes in the management of inflammatory joint diseases. This has been most obvious with advances in treatments for rheumatoid arthritis (RA). However, steady progress is also being made in treating lupus and other autoimmune rheumatic conditions. In this issue of the MJA, several articles discuss these developments along with current challenges.